The Supreme Court of Iowa handed Schwarz Pharma Inc. and Pfizer Inc. a win on Friday, affirming that the companies don’t have to face claims from a woman who took a generic version of Schwarz’s brand name drug Reglan. The woman’s lawyers had argued that her claims against the brand drugmakers should be reinstated under a theory known as innovator liability, but the court called such an approach a “slippery slope.”
“We are unwilling to make brand manufacturers the de facto insurers for competing generic manufacturers,” Iowa Supreme Court Justice Thomas Waterman wrote in Friday’s 91-page decision.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
